REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
REGN is not a clear buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock remains fundamentally strong, but the recent failed LAG-3 trial has reduced near-term upside and analyst targets have generally come down. The technical picture is positive but extended, and with no AI Stock Picker or SwingMax signal, I would wait rather than buy aggressively at this level.
REGN is in an upward-to-neutral trend. MACD histogram is strongly positive at 6.56 and expanding, which supports bullish momentum. However, RSI_6 at 78.666 suggests the stock is overbought in the short term even though it is labeled neutral in the source. Moving averages are converging, which indicates the trend is not fully accelerating. Price at 651.53 is near resistance (R1 647.921 already broken intraday, R2 662.089 next), with pivot support at 624.988. This suggests upside is possible, but the entry is not especially attractive for a beginner buying now.
["Core commercial strength remains intact, especially Dupixent-related economics and Eylea HD momentum.", "Hedge funds are buying, with buying activity up 167% over the last quarter.", "Options flow is mildly bullish with call-heavy positioning.", "Several analysts still maintain Buy/Outperform ratings and see support from cash and core assets.", "The stock has short-term bullish technical momentum with a positive and expanding MACD."]
["The Phase 3 fianlimab/LAG-3 melanoma trial missed its primary endpoint, removing a major growth catalyst.", "Analysts have cut price targets broadly after the trial miss, showing weaker forward expectations.", "Leerink downgraded the stock to Market Perform and now sees more risk to EPS and revenue downside.", "Congress trading data shows 1 sale and 0 purchases in the last 90 days, which is a cautious signal.", "The stock is near short-term resistance and may be extended after the recent move."]
No quarterly financial snapshot was provided, so I cannot assess the latest reported quarter directly. Based on the analyst commentary, the business still appears to have strong commercial performance in core franchises such as Dupixent and improving Eylea HD trends, but pipeline disappointment is pressuring forward growth expectations.
Recent analyst sentiment has turned more cautious. Multiple firms lowered price targets after the fianlimab Phase 3 miss, including Canaccord to $875, Wolfe to $860, Truist to $778, RBC to $707, Evercore to $825, Piper to $855, BMO to $730, and JPMorgan to $850. Most firms kept Buy/Outperform-type ratings, while Leerink downgraded to Market Perform with a $641 target. The Wall Street pros view is mixed: bulls still like REGN's strong core assets and cash support, but bears focus on pipeline disappointment, possible Eylea pressure, and reduced long-term growth visibility.
